Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oxygen 2l/min

PreclinicalSmall molecule

IInsel Gruppe AG, University Hospital Bern

Oxygen 2l/min is one of 2 small molecule programs targeting Oxygenation. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

OxygenationCompleted

OxygenationPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Oxygenation

#DrugCompanyPhaseTrials

NORADRENALIN

UUniversity of Aarhus

Oxygen 2l/min

IInsel Gruppe AG, University Hospital Bern

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oxygenation1 trial

Physiology Regarding Apnoeic Oxygenation During Nasal Cannula Therapy at Different Flow Rates

Completed·IInsel Gruppe AG, University Hospital Bern·N/A·NCT03478774·125 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Oxygen 2l/min. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oxygen 2l/min compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oxygen 2l/min. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Insel Gruppe AG, University Hospital Bern company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInsel Gruppe AG, University Hospital Bern

Related News